Filing Flows

Filing Flows › Quest Diagnostics (DGX) › Guidance history

Quest Diagnostics (DGX) guidance history: what it guided and what it reported

Quest Diagnostics gave guidance in 12 earnings releases on file since Feb 1, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.3% against the guided midpoint. Its releases raised guidance 8 times and lowered it 0 times.

Revenue

Quest Diagnostics Revenue: last guidance vs reportedQuest Diagnostics Revenue: last guidance vs reportedguided rangereported (above / within / below)FY2024$9.9BFY2025$11.0BFY2026

Met or beat 2 of 2 periods (2 above, 0 within, 0 below).

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$11.7B–$11.8B (Feb 10, 2026) → reaffirmed $11.8B (Apr 21, 2026) → raised $11.9B–$12.1B (Jul 23, 2026) → raised $12.1B–$12.1B (Oct 22, 2026)—to be reported—
FY2025$10.7B (Jan 30, 2025) → reaffirmed $10.7B (Apr 22, 2025) → raised $10.8B (Jul 22, 2025)$11.0Babove the range+2.2%
FY2024$9.3B (Feb 1, 2024) → raised $9.4B–$9.5B (Apr 23, 2024) → raised $9.5B–$9.6B (Jul 23, 2024) → raised $9.8B–$9.8B (Oct 22, 2024)$9.9Babove the range+0.5%

GAAP EPS

This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$9.45–$9.65 (Feb 10, 2026) → raised $9.58–$9.78 (Apr 21, 2026) → raised $9.97–$10.17 (Jul 23, 2026) → raised $10.21–$10.31 (Oct 22, 2026)—to be reported—
FY2025$8.34–$8.59 (Jan 30, 2025) → raised $8.62–$8.87 (Apr 22, 2025) → lowered $8.60–$8.80 (Jul 22, 2025) → lowered $8.58–$8.66 (Oct 21, 2025)———
FY2024$7.69–$7.99 (Feb 1, 2024) → lowered $7.57–$7.82 (Apr 23, 2024) → lowered $7.57–$7.77 (Jul 23, 2024) → lowered $7.60–$7.70 (Oct 22, 2024)———

Capital expenditures

The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$550M (Feb 10, 2026) → reaffirmed $550M (Apr 21, 2026) → reaffirmed $550M (Jul 23, 2026) → reaffirmed $550M (Oct 22, 2026)—to be reported—
FY2025$500M (Jan 30, 2025) → reaffirmed $500M (Apr 22, 2025) → reaffirmed $500M (Jul 22, 2025) → reaffirmed $500M (Oct 21, 2025)$527M (GAAP)not judged—
FY2024$420M (Feb 1, 2024) → reaffirmed $420M (Apr 23, 2024) → reaffirmed $420M (Jul 23, 2024)$425M (GAAP)not judged—

Adjusted EPS

The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$10.50–$10.70 (Feb 10, 2026) → raised $10.63–$10.83 (Apr 21, 2026) → raised $11.05–$11.25 (Jul 23, 2026) → raised $11.25–$11.35 (Oct 22, 2026)—to be reported—
FY2025$9.55–$9.80 (Jan 30, 2025) → reaffirmed $9.55–$9.80 (Apr 22, 2025) → raised $9.63–$9.83 (Jul 22, 2025) → raised $9.76–$9.84 (Oct 21, 2025)———
FY2024$8.60–$8.90 (Feb 1, 2024) → raised $8.72–$8.97 (Apr 23, 2024) → raised $8.80–$9.00 (Jul 23, 2024) → reaffirmed $8.85–$8.95 (Oct 22, 2024)———

The latest quarter

Quest Diagnostics, Q3 2026: revenue $3.1B (+10% year over year), operating margin 15.5%, net earnings $312M, operating cash flow $611M. The chart follows the revenue to costs, profit and cash.

Questions

Does Quest Diagnostics beat its guidance?

Quest Diagnostics gave guidance in 12 earnings releases on file since Feb 1, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.3% against the guided midpoint.

How often does Quest Diagnostics raise guidance?

Its earnings releases raised guidance 8 times and lowered it 0 times since Feb 1, 2024.

Latest guidance and outlook →

Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.